retatrutide nejm Phase 2 Trial of for Obesity Retatrutide Phase 2 NEJM Trial:

At the neurochemical level, preclinical studies demonstrate that GLP-1 RAs modulate dopamine levels and glutamatergic neurotransmission in reward circuits, attenuate accumbal dopamine release in response to drugs of abuse and suppress phasic dopamine responses to food-predictive cues in the VTA

Two distinct modes of hypoosmotic medium-induced release of excitatory amino acids and taurine in the rat brain in vivo

Beta-blockers are sometimes used if symptoms are very bothersome

Plants-Basel 12, 1049

His team tracked 7,938 adult patients in Ohio and Florida who had started injectable semaglutide or tirzepatide and then stopped the medication between three and twelve months after beginning treatment

This figure was partially created with BioRender.com (the Y-maze)